Bazedoxifene + Conjugated Estrogens (Duavee): The Complete Clinical Guide

What Is Bazedoxifene/Conjugated Estrogens and How Does It Work?

Duavee is the only approved tissue-selective estrogen complex (TSEC): conjugated estrogens supply the estrogenic activity that relieves hot flashes and protects bone, while bazedoxifene, a third-generation SERM, blocks estrogen receptors in uterine tissue so the endometrium is not stimulated. That pairing eliminates the need for a progestogen in women with an intact uterus, which matters because progestin side effects, such as bloating, mood changes, and breast tenderness, are a leading reason women discontinue HRT.

The mechanism differs from standard estrogen-plus-progestogen therapy. Bazedoxifene acts as an estrogen antagonist in the breast and uterus while behaving as a partial agonist in bone, making it functionally similar to raloxifene (Evista) but more potent in the uterine protection context. The FDA's prescribing label summarizes the dual action: "Conjugated estrogens provide estrogenic activity. Bazedoxifene is a SERM that acts as an estrogen agonist/antagonist. The effects of CE/BZA are a composite of the estrogenic and anti-estrogenic effects of its components." [1]

Two pharmacokinetic points clinicians watch: bazedoxifene has an oral bioavailability of roughly 6% because of heavy first-pass glucuronidation, and steady-state plasma levels are reached within 7 days of daily dosing. Food does not meaningfully alter BZA exposure, so the tablet may be taken without regard to meals, though the prescribing information notes that a high-fat meal increased CE Cmax by about 30%, which is generally not clinically significant at the approved dose. [1]

Clinical Evidence: What the SMART Trials Showed

The SMART (Selective estrogens, Menopause, And Response to Therapy) trial series is the core evidence base. Five Phase 3 randomized controlled trials enrolled postmenopausal women with an intact uterus across multiple countries.

SMART-2 (N=318 per active arm) was the key vasomotor-symptom trial. At week 12, women receiving CE 0.45 mg/BZA 20 mg averaged 74% fewer moderate-to-severe hot flashes per day compared with baseline, versus 51% in the placebo group (P<0.001). [2] The difference from placebo was statistically significant from week 4 onward.

SMART-1 (N=3,397, 24-month duration) demonstrated endometrial safety. The cumulative incidence of endometrial hyperplasia with CE 0.45 mg/BZA 20 mg was 0.0%, meeting the pre-specified non-inferiority criterion against the 2% regulatory threshold. [3] Progestogen-only arms in the same study confirmed that BZA alone provided endometrial protection equivalent to medroxyprogesterone acetate 1.5 mg.

SMART-5 evaluated sleep disturbance directly. Women on CE/BZA 20 mg reported a 44% reduction in sleep disturbance scores at 12 weeks compared with 26% on placebo. [4] Bone mineral density data from SMART-1 showed that lumbar spine BMD increased by 1.51% at 24 months with CE 0.45 mg/BZA 20 mg versus a loss of 1.22% with placebo (between-group difference P<0.001). [3]

The Menopause Society (formerly NAMS) 2023 position statement notes that CE/BZA is "an appropriate option for postmenopausal women with a uterus who prefer to avoid progestogen" and assigns it a Level I evidence grade for vasomotor symptom relief. [5]

Who Is an Appropriate Candidate?

Women most likely to benefit from CE/BZA share a specific profile: they have a uterus, experience moderate-to-severe vasomotor symptoms (defined as 7 or more hot flashes per day or 50 or more per week in the SMART trials), and have a reason to avoid progestogens. Common progestogen avoidance reasons include a personal or family history of progestin-associated depression, recurrent breast tenderness on combined HRT, or simply a preference for fewer synthetic hormones.

CE/BZA is NOT appropriate after hysterectomy. Women without a uterus need no endometrial protection, so the added SERM provides no clinical benefit while adding cost. For those patients, conjugated estrogens alone or any estradiol formulation is the more rational choice. [1]

Additional contraindications from the FDA label include: undiagnosed abnormal genital bleeding, known or suspected estrogen-dependent neoplasia, active or prior venous thromboembolism, active or recent arterial thromboembolic disease (stroke or MI within 12 months), liver dysfunction or disease, known protein C or protein S or antithrombin deficiency, and pregnancy. [1]

Age and timing also shape the risk-benefit calculation. The Menopause Society states that "for women aged younger than 60 years or within 10 years of menopause onset, the benefits of hormone therapy for bothersome vasomotor symptoms most likely outweigh the risks for the majority of women." [5] CE/BZA fits within that favorable window when started appropriately.

Dosing, Administration, and Practical Notes

One tablet daily, always. Each tablet contains CE 0.45 mg and BZA 20 mg. There is no approved dose titration, making this simpler to prescribe than estradiol patches where clinicians adjust from 0.025 mg/day to 0.1 mg/day based on response.

A clinically important drug interaction: concurrent use of CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort) can reduce BZA plasma concentrations by up to 56%, potentially compromising endometrial protection. [1] That is not a theoretical concern. Any patient starting an enzyme-inducing anticonvulsant while on Duavee needs a progestogen added or a switch to a different HRT regimen.

Annual reassessment is standard practice per the Menopause Society. The 2023 position statement advises clinicians to use "the lowest effective dose for the shortest duration consistent with treatment goals, benefits, and risks for the individual woman." [5] For CE/BZA, there is no lower-dose option below 0.45/20 mg, so if symptoms resolve and osteoporosis prevention is no longer the goal, transitioning to a lower-dose transdermal estradiol-plus-IUD or estradiol-plus-progestogen regimen may be appropriate.

Bazedoxifene/CE Versus Estradiol: Route-by-Route Comparison

Standard HRT uses estradiol, not conjugated estrogens. Understanding the practical and pharmacological differences helps clinicians select the best fit for each patient.

Oral Estradiol (e.g., Estrace 0.5, 1 to 2 mg)

Oral estradiol undergoes extensive first-pass hepatic conversion to estrone, raising the estrone:estradiol ratio to roughly 5:1 in serum. This first-pass effect also increases hepatic synthesis of sex hormone-binding globulin (SHBG), triglycerides, C-reactive protein, and coagulation factors, which may contribute to the small increase in VTE risk associated with oral estrogens. A large nested case-control study (N=80,396) published in the BMJ found oral estrogen associated with an odds ratio of 1.58 for VTE versus a 0.96 odds ratio for transdermal estrogen. [6] CE/BZA is oral, so it carries the same hepatic first-pass exposure as oral estradiol.

Estradiol Patch (e.g., Vivelle-Dot, Climara: 0.025 to 0.1 mg/day)

Transdermal patches deliver estradiol directly into the bloodstream through the skin, bypassing the liver entirely. Twice-weekly (Vivelle-Dot) or once-weekly (Climara) patch changes suit women who want less daily involvement. Patches may cause local adhesive reactions in 5 to 17% of users in trials, and adhesion can be an issue in hot or humid climates. They require a separate progestogen for women with a uterus (or a levonorgestrel IUD), which CE/BZA eliminates. A 2022 Cochrane review of 801 RCTs in postmenopausal women found transdermal estradiol equally effective to oral estradiol for vasomotor symptoms with a more favorable VTE profile. [7]

Estradiol Gel (Divigel 0.1%: 0.25 g, 0.5 g, 1.0 g packets)

Divigel is applied once daily to the upper thigh in unit-dose packets. The 0.25 g dose delivers approximately 0.25 mg estradiol; the 1.0 g dose delivers 1.0 mg. A Phase 3 RCT of Divigel (N=495 to 12 weeks) showed a 73% reduction in moderate-to-severe hot flash frequency at the 1.0 g/day dose versus 51% with placebo. [8] Gel allows flexible dose titration, which CE/BZA does not. Transfer of gel to partners or children through skin contact is a labeling safety concern that does not apply to oral CE/BZA. Women with a uterus using Divigel still need progestogen protection.

Estradiol Spray (Evamist: 1.53 mg per spray)

Evamist delivers 1.53 mg estradiol per metered spray applied to the inner forearm. Most women use one to three sprays daily. The Phase 3 trial (N=417 to 12 weeks) showed a 60% reduction in mean hot flash frequency with three sprays versus 40% placebo reduction. [9] Like gels, sprays require progestogen in women with a uterus. The spray format suits women with skin conditions that preclude patch adhesives, or those who find gel application messy. Accidental transfer to children has been reported to the FDA, so application site coverage is recommended. [9]

The table below summarizes the main trade-offs:

| Feature | CE/BZA (Duavee) | Oral Estradiol | Patch | Gel (Divigel) | Spray (Evamist) | |---|---|---|---|---|---| | Route | Oral | Oral | Transdermal | Transdermal | Transdermal | | First-pass hepatic effect | Yes | Yes | No | No | No | | Progestogen required (intact uterus) | No | Yes | Yes | Yes | Yes | | Dose flexibility | No (fixed) | Yes | Yes | Yes | Yes | | Dosing frequency | Daily | Daily | 2x/week or weekly | Daily | Daily | | Post-hysterectomy use | Not indicated | Yes | Yes | Yes | Yes |

Breast Safety and Cancer Risk Considerations

Breast outcomes from CE/BZA trials are reassuring so far, though the evidence base is narrower than the decades of data behind estrogen-progestogen regimens. In SMART-1 (24 months), breast pain occurred in 3.0% of CE 0.45 mg/BZA users versus 4.3% for CE 0.45 mg plus medroxyprogesterone acetate 1.5 mg and 2.0% for placebo. [3] Mammographic breast density, a surrogate marker for breast cancer risk, did not increase significantly with CE/BZA in the 2-year trial period, which contrasts with the increase seen on CE plus medroxyprogesterone acetate.

Long-term breast cancer data are not yet available at the scale of the Women's Health Initiative (N=16,608). The WHI showed that estrogen-alone (in hysterectomized women) was actually associated with a reduced breast cancer hazard ratio of 0.77, while CE plus medroxyprogesterone acetate was associated with an increased HR of 1.24. [10] Because CE/BZA replaces the progestin with a SERM, the working hypothesis is that its breast risk profile will resemble CE alone, but this has not been confirmed in a long-term superiority trial.

Clinicians should continue annual breast exams and age-appropriate mammography screening per USPSTF guidelines regardless of which HRT formulation a woman uses. [11]

Managing Expectations: What CE/BZA Will and Will Not Do

CE/BZA is effective for hot flashes, night sweats, sleep disruption, and osteoporosis prevention. It does not improve genitourinary syndrome of menopause (GSM) as well as local vaginal estrogen preparations do. Women with prominent GSM symptoms (vaginal dryness, dyspareunia, recurrent UTIs) may need low-dose vaginal estradiol or estriol added to their CE/BZA regimen. The FDA label explicitly permits concurrent low-dose vaginal estrogen at clinician discretion.

Sexual function data from SMART trials were secondary endpoints. SMART-3 (N=664) reported modest but statistically significant improvements in sexual desire domain scores on CE 0.45 mg/BZA 20 mg versus placebo at 12 weeks. These improvements were likely mediated through vasomotor symptom relief rather than direct estrogenic effects on libido, since systemic estrogen does not reliably increase sexual desire by itself. Women with persistent low libido after vasomotor symptom control may warrant evaluation for testosterone insufficiency.

CE/BZA does not prevent cardiovascular disease. The current FDA label carries the same black-box cardiovascular and stroke warnings as all systemic estrogen products, reflecting data from the WHI estrogen-progestogen arm. Neither CE/BZA nor any HRT should be prescribed primarily for cardiovascular risk reduction. [1]

Safety Monitoring and Follow-Up Protocol

Baseline evaluation before prescribing CE/BZA should include: a thorough personal and family history of cancer and thromboembolism, blood pressure measurement, pelvic exam, and age-appropriate mammography. Liver function tests are warranted if hepatic disease is suspected given that BZA is hepatically metabolized. Endometrial biopsy is not routinely required before starting CE/BZA given the Class 1 endometrial safety data, though any unexplained uterine bleeding before initiation should be investigated.

At 3 months, a follow-up visit to assess symptom response and tolerability is reasonable. Women who experience breakthrough bleeding on CE/BZA should have it evaluated promptly. The SMART-1 cumulative bleeding rate (any bleeding or spotting) was 6.3% at 12 months for CE 0.45 mg/BZA 20 mg versus 4.7% for placebo, which is lower than most combined estrogen-progestogen regimens. [3]

Bone mineral density monitoring by DXA scan is recommended every 2 years if osteoporosis prevention is a primary indication, consistent with the National Osteoporosis Foundation guidance. Women already on CE/BZA purely for vasomotor symptom control who have normal baseline BMD do not necessarily need DXA reassessment annually.